Patent intelligence · US
US 8796270
N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a S…
Patent details — US 8796270
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 5, 2014
- Expiration
- Jul 31, 2034
- Applicant
- GILEAD CONNECTICUT, INC.
- Claims
- 7
- CPC classes
- A61K, A61K9/0053, A61P, A61P1/00
Quick answer
US 8796270 (N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor) is held by GILEAD CONNECTICUT, INC.. Status: granted. Granted Aug 5, 2014. Expires Jul 31, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GILEAD CONNECTICUT, INC.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K9/0053, A61P, A61P1/00, A61P11/00, A61P11/02
More from GILEAD CONNECTICUT, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12311017
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 12251378
Long-acting local anesthetic formulation
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12029787
Method for generating recombinant poxviruses
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted
Frequently asked questions
What is US patent 8796270?
US 8796270 (N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor) is held by GILEAD CONNECTICUT, INC.. Status: granted. Granted Aug 5, 2014. Expires Jul 31, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8796270?
GILEAD CONNECTICUT, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 179 pharmaceutical patents for this assignee.
When does US 8796270 expire?
Our index shows an expiration date of Jul 31, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.